Rosiglitazone
- Generic Name
- Rosiglitazone
- Brand Names
- Avandamet, Avandia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O3S
- CAS Number
- 122320-73-4
- Unique Ingredient Identifier
- 05V02F2KDG
- Background
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellula...
- Indication
Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Rosiglitazone and Insulin in T1DM Adolescents
- Conditions
- First Posted Date
- 2006-09-06
- Last Posted Date
- 2006-09-06
- Lead Sponsor
- The University of New South Wales
- Target Recruit Count
- 32
- Registration Number
- NCT00372086
- Locations
- 🇦🇺
Sydney Children's Hospital, Sydney, New South Wales, Australia
11ß-HSD1 and Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 24
- Registration Number
- NCT00370305
- Locations
- 🇩🇪
Charite, Campus Benjamin Franklin, Berlin, Germany
Rosiglitazone Effect on Mitochondria and Lipoatrophy
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2017-02-06
- Target Recruit Count
- 71
- Registration Number
- NCT00367744
- Locations
- 🇺🇸
Cleveland Clinc Foundation, Cleveland, Ohio, United States
🇺🇸University Hospitals of Cleveland/Case Western Reserve University, Cleveland, Ohio, United States
Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome
- Conditions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2012-11-22
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT00364221
- Locations
- 🇺🇸
University of Colorado at Denver and Health Sciences Center General Clinical Research Center, Denver, Colorado, United States
Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI
- Conditions
- Interventions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2008-06-27
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT00361868
- Locations
- 🇩🇪
Site 405, Berlin, Germany
🇭🇷Site105, Pula, Croatia
🇭🇷Site102, Rijeka, Croatia
AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 544
- Registration Number
- NCT00359112
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy
- Conditions
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 220
- Registration Number
- NCT00358124
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)
- Conditions
- Interventions
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 262
- Registration Number
- NCT00350779
Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 301
- Registration Number
- NCT00348712
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, York, United Kingdom
Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2011-03-17
- Lead Sponsor
- Intermountain Health Care, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00343395
- Locations
- 🇺🇸
Intermountain Medical Center, Murray, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.